{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:54:31Z","timestamp":1781513671866,"version":"3.54.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) has been associated with reduced transaminase level among people with HIV (PWH), with and without HBV. It is unclear whether the effect is mediated by HBV serostatus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a longitudinal observational study of PWH who switched from TDF to TAF between 2016 and 2023. A mixed-effects model with random intercepts assessed the effect of the switch on transaminases, including an interaction term for HBV status: chronic hepatitis B (HBsAg+), possible occult HBV infection (pOBI; HBsAg\u2212\/HBcAb+) and no HBV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 727 individuals, 7% had chronic hepatitis B and 35% had pOBI. Switching to TAF was associated with a significant ALT decrease (\u03b2 \u22123.5\u2005UI\/mL, 95%CI: \u22125.2 to \u22121.9). Compared to HBV-negative individuals, individuals with chronic hepatitis B experienced steeper ALT reduction (\u03b2 \u22127.5, 95%CI: \u221211.8 to \u22123.2), while pOBI was associated with a non-significant reduction (\u03b2 \u22121.9; 95%CI: \u22124.4\u20130.6; P\u200a=\u200a0.133). These findings persisted after adjusting for other predictors of transaminase levels. TAF was also associated with accelerated weight gain (+0.75\u2005kg\/year, 95% CI: 0.63\u20130.87) and a transient drop in the Hepatic Steatosis Index (\u22120.22; 95% CI: \u22120.38 to \u22120.06) followed by an annual increase thereafter (+0.18\/year; 95% CI: 0.10\u20130.27).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switching from TDF to TAF is associated with modest but statistically significant ALT reduction in PWH, especially in HBsAg\u200a+\u200aindividuals. Our findings suggest that TAF may represent a favourable option in this subgroup, although potential metabolic consequences warrant close monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag045","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:11:20Z","timestamp":1769515880000},"source":"Crossref","is-referenced-by-count":0,"title":["HBV status modulates transaminase decrease after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV"],"prefix":"10.1093","volume":"81","author":[{"given":"Giuseppe","family":"Lapadula","sequence":"first","affiliation":[{"name":"School of Medicine, University of Milano-Bicocca , Milan ,","place":["Italy"]},{"name":"Infectious Diseases Unit, IRCCS Fondazione San Gerardo dei Tintori , Monza (MB) ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Soria","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS Fondazione San Gerardo dei Tintori , Monza (MB) ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1040-4191","authenticated-orcid":false,"given":"Laura","family":"Antolini","sequence":"additional","affiliation":[{"name":"Bicocca Bioinformatics Biostatistics and Bioimaging Center - B4, University of Milano-Bicocca , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Rugova","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS Fondazione San Gerardo dei Tintori , Monza (MB) ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Colella","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS Fondazione San Gerardo dei Tintori , Monza (MB) ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sabbatini","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS Fondazione San Gerardo dei Tintori , Monza (MB) ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Squillace","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS Fondazione San Gerardo dei Tintori , Monza (MB) ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5652-3204","authenticated-orcid":false,"given":"Luca","family":"Mezzadri","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Milano-Bicocca , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Limonta","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS Fondazione San Gerardo dei Tintori , Monza (MB) ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cappelletti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS Fondazione San Gerardo dei Tintori , Monza (MB) ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Ranzani","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS Fondazione San Gerardo dei Tintori , Monza (MB) ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bonfanti","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Milano-Bicocca , Milan ,","place":["Italy"]},{"name":"Infectious Diseases Unit, IRCCS Fondazione San Gerardo dei Tintori , Monza (MB) ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"2026061504161589100_dkag045-B1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study","volume":"16","author":"Mills","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2026061504161589100_dkag045-B2","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"2026061504161589100_dkag045-B3","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1097\/QAD.0000000000002223","article-title":"Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials","volume":"33","author":"Gupta","year":"2019","journal-title":"AIDS"},{"key":"2026061504161589100_dkag045-B4","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1111\/jgh.16593","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B","volume":"39","author":"Nam","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"2026061504161589100_dkag045-B5","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1002\/jmv.27863","article-title":"Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate","volume":"94","author":"Liang","year":"2022","journal-title":"J Med Virol"},{"key":"2026061504161589100_dkag045-B6","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/hep.31793","article-title":"Treatment and renal outcomes up to 96 weeks after tenofovir alafenamide switch from tenofovir disoproxil fumarate in routine practice","volume":"74","author":"Toyoda","year":"2021","journal-title":"Hepatology"},{"key":"2026061504161589100_dkag045-B7","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.2147\/DDDT.S274307","article-title":"The effect of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) on liver enzymes, glucose, and lipid profile","volume":"14","author":"Squillace","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"2026061504161589100_dkag045-B8","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/hiv.13106","article-title":"Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study","volume":"22","author":"Kovari","year":"2021","journal-title":"HIV Med"},{"key":"2026061504161589100_dkag045-B9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/QAI.0000000000003079","article-title":"Brief report: effect of antiretroviral switch from tenofovir disoproxil fumarate to tenofovir alafenamide on alanine aminotransferase, lipid profiles, and renal function in HIV\/HBV-coinfected individuals in a Nationwide Canadian Study","volume":"91","author":"Sarowar","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026061504161589100_dkag045-B10","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1111\/liv.15261","article-title":"Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-na\u00efve chronic hepatitis B","volume":"42","author":"Lim","year":"2022","journal-title":"Liver Int"},{"key":"2026061504161589100_dkag045-B11","doi-asserted-by":"publisher","first-page":"e37953","DOI":"10.1097\/MD.0000000000037953","article-title":"Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B","volume":"103","author":"Liu","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"2026061504161589100_dkag045-B12","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1097\/QAD.0000000000002233","article-title":"Clinical significance of elevated liver transaminases in HIV-infected patients","volume":"33","author":"Cai","year":"2019","journal-title":"AIDS"},{"key":"2026061504161589100_dkag045-B13","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1097\/QAD.0000000000001018","article-title":"Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons","volume":"30","author":"Ryom","year":"2016","journal-title":"AIDS"},{"key":"2026061504161589100_dkag045-B14","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1097\/QAD.0000000000004227","article-title":"Hepatitis B core antibody positivity is not associated with risk of transaminase elevation following switch to dual antiretroviral therapy","volume":"39","author":"Mezzadri","year":"2025","journal-title":"AIDS"},{"key":"2026061504161589100_dkag045-B15","doi-asserted-by":"publisher","first-page":"758","DOI":"10.7326\/M20-4853","article-title":"Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: a cohort study","volume":"174","author":"Surial","year":"2021","journal-title":"Ann Intern Med"},{"key":"2026061504161589100_dkag045-B16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"key":"2026061504161589100_dkag045-B17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026061504161589100_dkag045-B18","doi-asserted-by":"publisher","first-page":"e652","DOI":"10.1093\/cid\/ciac621","article-title":"Metabolic-related outcomes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in adults with human immunodeficiency virus (HIV): a multicenter prospective cohort study","volume":"76","author":"Mart\u00ednez-Sanz","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026061504161589100_dkag045-B19","doi-asserted-by":"publisher","first-page":"e640","DOI":"10.1016\/S2352-3018(23)00151-0","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial","volume":"10","author":"Avihingsanon","year":"2023","journal-title":"Lancet HIV"},{"key":"2026061504161589100_dkag045-B20","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1128\/AAC.00128-15","article-title":"Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy","volume":"59","author":"Murakami","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026061504161589100_dkag045-B21","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1097\/QAD.0000000000001744","article-title":"Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide","volume":"32","author":"Podany","year":"2018","journal-title":"AIDS"},{"key":"2026061504161589100_dkag045-B22","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1177\/0956462420983699","article-title":"Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group","volume":"32","author":"\u0141omiak","year":"2021","journal-title":"Int J STD AIDS"},{"key":"2026061504161589100_dkag045-B23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/QAI.0000000000003101","article-title":"Weight gain and metabolic effects in persons with HIV who switch to ART regimens containing integrase inhibitors or tenofovir alafenamide","volume":"92","author":"Palella","year":"2023","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026061504161589100_dkag045-B24","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/cid\/ciae191","article-title":"Antiretrovirals and weight change: weighing the evidence","volume":"79","author":"Wohl","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026061504161589100_dkag045-B25","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1016\/S2352-3018(25)00105-5","article-title":"Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial","volume":"12","author":"Ryan","year":"2025","journal-title":"Lancet HIV"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag045\/66840138\/dkag045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag045\/66840138\/dkag045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:16:32Z","timestamp":1781511392000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag045\/8471162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag045","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,2]]},"article-number":"dkag045"}}